Cochrane · systematic review · CD003382
Strategies for managing sexual dysfunction induced by antidepressant medication
Taylor, MJ, Rudkin, L, Bullemor‐Day, P, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 55.6%High 4 · 44.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Sildenafil versus placebo
Population: people with antidepressant‐induced sexual dysfunction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Endpoint International Index of Erectile Function (IIEF) total scores (The IIEF is a self‐report measure with 15 questions examining erectile function, orgasmic function, sexual desire, and intercourse satisfaction. Maximum possible score 75) Sildenafil vs placebo | no estimate extracted | 2 studies · 112 participants | High |
Endpoint International Index of Erectile Function (IIEF) scores ‐ question 3: ability to achieve erection (Maximum score 5) Sildenafil vs placebo | no estimate extracted | 2 studies · 231 participants | High |
Endpoint International Index of Erectile Function (IIEF) scores ‐ intercourse satisfaction (questions 6, 7, 8) (Maximum score 15) Sildenafil vs placebo | no estimate extracted | 1 study · 89 participants | Moderate |
Clinical Global Impression ‐Sexual Function not "much/very much improved" by endpoint Sildenafil vs placebo | RR 0.44 [0.33, 0.58] | 2 studies · 187 participants | Moderate |
Dropouts (People leaving the trial early) Sildenafil vs placebo | RR 0.68 [0.41, 1.14] | 4 studies · 353 participants | High |
Global Efficacy Questionnaire (questions 1 & 2) (Questions assessing improvement attributed to medication compared to having no treatment at all) Sildenafil vs placebo | RR 2.5 [1.67, 3.73] | 1 study · 284 participants | Moderate |
Bupropion versus placebo
Population: people with antidepressant‐induced sexual dysfunction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Endpoint scale total scores (150 mg twice daily dose) (Scales of sexual functioning. As studies used different scales to assess sexual functioning, differences are expressed as standardised mean differences (SMD)) Bupropion vs placebo | no estimate extracted | 3 studies · 482 participants | Moderate Downgraded: inconsistency |
50% reduction in score on the Arizona Sexual Experiences Scale (ASEX) (150 mg once daily dose) (The ASEX is a 5‐item self‐report inventory of sexual function) Bupropion vs placebo | RR 0.62 [0.09, 4.41] | 2 studies · 71 participants | Moderate Downgraded: inconsistency |
Dropouts (People leaving the trial early) Bupropion vs placebo | RR 1.08 [0.67, 1.72] | 5 studies · 579 participants | High |